Age-related macular degeneration: Current and novel therapies

Maturitas

Volumn 66, Issue 1, 2010, Pages 46-50

  Prasad, Pradeep S ^a,b   Schwartz, Steven D ^a,b   Hubschman, Jean Pierre ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

Author keywords

Antioxidant; Exudative; Macular degeneration; Neuroprotection; Nonexudative; Treatment; VEGF; Vitamin

Indexed keywords

ANTIOXIDANT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

CATARACT; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; INDUSTRIALIZATION; LASER COAGULATION; NUTRITIONAL SUPPORT; PHOTODYNAMIC THERAPY; PREVALENCE; PROGNOSIS; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; AGED; DIET SUPPLEMENTATION; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; VITREOUS BODY;

AGED; ANTIOXIDANTS; DIETARY SUPPLEMENTS; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; VITREOUS BODY;

EID: 77950866700     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.02.006     Document Type: Review

References (32)

1. Klein B.E., and Linton K.L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99 6 (1992) 933-943
2. Friedman D.S., O'Colmain B.J., Munoz B., et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122 4 (2004) 564-572
3. Thylefors B. A global initiative for the elimination of avoidable blindness. Am J Ophthalmol 125 1 (1998) 90-93
4. Stein J.D., Brown M.M., Brown G.C., et al. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol 87 (2003) 8-12
5. Bressler N.M., Bressler S.B., and Fine S.L. Age-related macular degeneration. Surv Ophthalmol 32 6 (1988) 375-413
6. Klaver C.C., Wolfs R.C., Assink J.J., et al. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 116 1 (1998) 1646-1651
7. Spraul C.W., Lang G.E., Grossniklaus H.E., et al. Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol 44 (1999) S10-S32
8. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1416-36.
9. Bressler N.M., Bressler S.B., Congdon N.G., et al. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 121 (2003) 1621-1624
10. Thornton J., Edwards R., Mitchell P., et al. Smoking and age-related macular degeneration: a review of association. Eye 19 (2005) 935-944
11. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1992;110:1701-8.
12. Seddon J.M., Cote J., and Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts and fish intake. Arch Ophthalmol 121 (2003) 1728-1737
13. Zhang C., Baffi J., Cousins S.W., et al. Oxidant-induced cell death in retinal pigment epithelium cells mediated through the release of apoptosis-inducing factor. J Cell Sci 116 (2003) 1915-1923
14. Decensi A., Robertson C., Guerrieri-Gonzaga A., et al. Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 27 August (23) (2009) 3749-3756
15. Petrukhin K. New therapeutic targets in atrophic age-related macular degeneration. Expert Opin Ther Targets 11 5 (2007) 625-639
16. Lotery A., and Trump D. Progress in defining the molecular biology of age related macular degeneration. Hum Genet 122 November (3-4) (2007) 219-236
17. Slakter J.S. Complement C3 inhibitor POT-4: pre-clinical safety of intra-vitreal and systemic administration. Oral presentation. The Retina Society, Boston, September (2007)
18. Emerich D.F., and Thanos C.G. NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther 10 October (5) (2008) 506-515
19. Binder S., Krebs I., Hilgrers H.D., et al. Outcome after transplantation of autologous RPE in age related macular degeneration-a prospective trial. Invest Ophthalmol Vis Sci 45 (2004) 4151-4160
20. Chaum E., and Hatton M.P. Gene therapy for genetic and acquired retinal disease. Surv Ophthalmol 47 (2002) 449-469
21. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 109 (1991) 1109-1114
22. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60.
23. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-Tap Report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45.
24. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. VEGF inhibition study in ocular neovascularization clinical trial group. N Engl J Med 351 27 (2004) 2805-2816
25. Rosenfeld P.J., Brown D.M., Heier J.S., et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 14 (2006) 1419-1431
26. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
27. Berrocal M.H., Lewis M.L., and Flynn H.W. Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol 122 (1996) 486-493
28. Borillo J.L., and Regillo C.D. Treatment of subretinal hemorrhage with tissue plasminogen activator. Curr Opin Ophthalmol 12 (2001) 207-211
29. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 111 11 (2004) 1967-1980
30. Falkner C.I., Leitich H., Frommlet F., et al. The end of submacular surgery for age-related macular degeneration? A meta-analysis. Graefes Arch Clin Exp Ophthalmol 245 4 (2007) 490-501
31. Reich S.J., Fosnot J., Kuoki A., et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9 (2003) 210-216
32. Holash J., Davis S., Papdopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99 17 (2002) 11393-11398